Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.

ABSTRACT:

Background

Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19.

Methods

A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted.

Results

A total of 259 patients were included in the analysis. The median overall survival (OS) among all patients, regardless of response, was 7.5 months (95% confidence interval [CI], 5.5-8.5 months); the median follow-up time for OS was 36.0 months (range, 0.3-60.8 months). The median relapse-free survival (RFS) among patients who achieved a complete remission (CR) or complete

SUBMITTER: Topp MS 

PROVIDER: S-EPMC7894150 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature